PGEN
Price
$1.43
Change
-$0.07 (-4.67%)
Updated
Jun 26 closing price
Capitalization
422.11M
45 days until earnings call
PRME
Price
$2.65
Change
+$0.23 (+9.50%)
Updated
Jun 26 closing price
Capitalization
347.93M
40 days until earnings call
Interact to see
Advertisement

PGEN vs PRME

Header iconPGEN vs PRME Comparison
Open Charts PGEN vs PRMEBanner chart's image
Precigen
Price$1.43
Change-$0.07 (-4.67%)
Volume$1.45M
Capitalization422.11M
Prime Medicine
Price$2.65
Change+$0.23 (+9.50%)
Volume$2.66M
Capitalization347.93M
PGEN vs PRME Comparison Chart in %
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PGEN vs. PRME commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a StrongBuy and PRME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (PGEN: $1.43 vs. PRME: $2.65)
Brand notoriety: PGEN and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 92% vs. PRME: 106%
Market capitalization -- PGEN: $422.11M vs. PRME: $347.93M
PGEN [@Biotechnology] is valued at $422.11M. PRME’s [@Biotechnology] market capitalization is $347.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • PGEN’s TA Score: 3 bullish, 5 bearish.
  • PRME’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than PGEN.

Price Growth

PGEN (@Biotechnology) experienced а -4.03% price change this week, while PRME (@Biotechnology) price change was +47.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

PGEN is expected to report earnings on Aug 11, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($422M) has a higher market cap than PRME($348M). PGEN YTD gains are higher at: 27.679 vs. PRME (-9.247). PGEN has higher annual earnings (EBITDA): -154.85M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. PGEN (80.2M). PGEN has less debt than PRME: PGEN (5.42M) vs PRME (121M). PGEN has higher revenues than PRME: PGEN (4.2M) vs PRME (3.85M).
PGENPRMEPGEN / PRME
Capitalization422M348M121%
EBITDA-154.85M-200M77%
Gain YTD27.679-9.247-299%
P/E RatioN/AN/A-
Revenue4.2M3.85M109%
Total Cash80.2M144M56%
Total Debt5.42M121M4%
FUNDAMENTALS RATINGS
PGEN vs PRME: Fundamental Ratings
PGEN
PRME
OUTLOOK RATING
1..100
2124
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4337
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
30n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (51) in the null industry is in the same range as PGEN (70). This means that PRME’s stock grew similarly to PGEN’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as PGEN (100). This means that PRME’s stock grew similarly to PGEN’s over the last 12 months.

PRME's SMR Rating (98) in the null industry is in the same range as PGEN (100). This means that PRME’s stock grew similarly to PGEN’s over the last 12 months.

PRME's Price Growth Rating (37) in the null industry is in the same range as PGEN (43). This means that PRME’s stock grew similarly to PGEN’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as PGEN (100). This means that PRME’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENPRME
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
N/A
Bearish Trend 16 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFEIX39.17N/A
N/A
JPMorgan Europe Dynamic L
FCIGX32.49N/A
N/A
Fidelity Advisor Small Cap Growth I
GTSYX30.60N/A
N/A
Invesco Small Cap Growth Y
PROVX18.97N/A
N/A
Provident Trust Strategy
WCMWX17.42N/A
N/A
WCM Focused Emerging Mkts Ex Chn Inst

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARCT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-4.67%
ARCT - PGEN
47%
Loosely correlated
+3.30%
CRSP - PGEN
45%
Loosely correlated
-0.17%
XENE - PGEN
44%
Loosely correlated
+1.39%
ALEC - PGEN
44%
Loosely correlated
+0.67%
PRME - PGEN
44%
Loosely correlated
+9.50%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+9.50%
CRSP - PRME
63%
Loosely correlated
-0.17%
RXRX - PRME
57%
Loosely correlated
+4.65%
BEAM - PRME
57%
Loosely correlated
+2.27%
CRBU - PRME
53%
Loosely correlated
-4.93%
CCCC - PRME
50%
Loosely correlated
-1.30%
More